Axsome Therapeutics vs TG Therapeutics
AXSM and TGTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AXSM and TGTX compare
TG Therapeutics is the larger company, worth 1.2 times as much as Axsome Therapeutics ($9.4B against $7.6B).
TG Therapeutics grew revenue faster over the last twelve months (76.1% versus 56.9% for Axsome Therapeutics).
TG Therapeutics keeps more of each dollar of sales as profit, with a net margin of 55.2% compared with −24.7% at Axsome Therapeutics.
TG Therapeutics scores higher on the StockData Score (10 against 8 for Axsome Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AXSM | TGTX |
|---|---|---|
| Size and price | ||
| Market cap | $7.6B | $9.4B |
| Share price | $144.43 | $61.18 |
| Change, 1 year | 8.3% | 81.1% |
| Change, 5 years | 259% | 72.3% |
| Beta (5Y) | 0.48 | 1.73 |
| Employees | 500 | 399 |
| StockData Score | ||
| Total score | 8 | 10 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 2 | 4 (better) |
| Health score | 3 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 22.3× |
| P/S | 9.7× (better) | 11.7× |
| P/B | 90.8× | 15.5× (better) |
| EV/EBITDA | – | 69.6× |
| P/FCF | – | 539× |
| FCF yield | −0.95% | 0.19% (better) |
| Fair value | – | $76.21 |
| Margin of safety | – | 19.7% |
| Growth | ||
| Revenue growth (TTM) | 56.9% | 76.1% (better) |
| Revenue growth, 5Y average | – | 427% |
| Net income growth (TTM) | – | 630% |
| EPS growth (TTM) | – | 641% |
| Profitability | ||
| Gross margin | 93.2% (better) | 82.4% |
| Operating margin | −24.0% | 17.1% (better) |
| Net margin | −24.7% | 55.2% (better) |
| FCF margin | −9.3% | 2.2% (better) |
| Return on equity | −245% | 100% (better) |
| Return on invested capital | – | 27.8% |
| Financial health | ||
| Debt / equity | 2.26 | 1.23 (better) |
| Net debt / EBITDA | – | 0.98 |
| Interest coverage | – | 3.6× |
| Current ratio | 1.43 | 4.27 (better) |
| Altman Z-score | 4.60 | 5.93 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | −0.47% | 1.9% (better) |
| Shareholder yield | −0.47% | 1.9% (better) |
| Ownership | ||
| Held by institutions | 73.8% | 72.6% |
| Held by insiders | 15.2% | 16.1% |
| Insider net buying, 12 months | −$134M | −$438K (better) |
| Short interest, % of float | 7.4% | 23.8% |
Go deeper
- AXSM stock overview
- AXSM income statement
- AXSM valuation and score
- TGTX stock overview
- TGTX income statement
- TGTX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.